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ABSTRACT 
To develop bromelain capped gold nanoparticles (BRN capped Au-NPs) as the effective drug delivery carriers of 
the antibiotic levofloxacin (LvN) and evaluate antibacterial potential of its bioconjugated form compared to pure 
LvN. BRN capped Au-NPs were synthesized by in vitro method and bioconjugated to LvN using 1-ethyl-3-(3-
dimethylamino-propyl)-carbodiimide as activator to form Au-BRN-LvN-NPs. These were characterized for 
mean particle size by dynamic light scattering analysis, zeta potential by Zetasizer nanosystem analysis and 
transmission electron microscopy (TEM) on carbon coated TEM copper grids by TEM respectively. Drug load-
ing efficiency of LvN was calculated using UV-visible spectroscopy by standard curve of pure LvN. Antibacte-
rial efficacy of Au-BRN-LvN-NPs and pure LvN was determined by evaluating minimum inhibitory concentra-
tion (MIC) against Staphylococcus aureus and Eschereschia coli. Two peaks were observed in Au-BRN-LvN-
NPs spectrum one at 307 nm and other at 526 nm while one peak in BRN capped Au-NPs at 522 nm during UV 
spectroscopy suggesting red shift. The drug loading efficiency of LvN was found to be 84.8 ± 2.41 %. The diam-
eter of Au-BRN-LvN-NPs and BRN capped Au-NPs were found to be (58.65 ± 2 nm, 38.11 ± 2 nm), zeta poten-
tial (-9.01 mV, -13.8 mV) and surface morphology (~13.2 nm, 11.4 nm) respectively. The MICs against S. aure-
us and E. coli were found to be (0.128 µg/mL, 1.10 µg/mL) for Au-BRN-LvN-NPs and (0.547 µg/mL, 1.96 
µg/mL) for pure LvN. The results suggested that BRN capped Au-NPs can be used as effective drug delivery 
carriers of the antibiotic LvN. The Au-BRN-LvN-NPs exhibited enhanced antibacterial activity compared to 
pure LvN alone. (Graphical abstract see Figure 1) 
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Figure 1: Graphical abstract
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INTRODUCTION 
The metallic nanoparticles derived from 
noble metals such as gold has attracted the 
researchers all over the world regarding their 
escalating use in delivery of drugs (Emerich 
and Thanos, 2006). These particles build up 
new physico-chemical properties which are 
absent in individual molecules. Specially, the 
gold nanoparticles are being targeted nowa-
days by the researchers since it not only en-
compasses the advantages of “nano-sizing” 
but it also includes surface functionalization 
necessary to augment stability and enable 
conjugation with biomolecules (Couto et al., 
2016). Surface functionalization of the gold 
nanoparticles has opened new frontiers for 
delivery of drugs such as anticancer and the 
antimicrobial drugs (Dhar et al., 2008, Selva-
raj and Alagar, 2007). Bovine serum albumin 
capped gold nanoparticles of amino-
glycosidic antibiotics and the acridine deriv-
atives bioconjugated on citrate stabilized 
gold nanoparticles have been used as the ef-
fective drug delivery vehicles (Rastogi et al., 
2012, Mitra et al, 2014). Thus, these exciting 
approaches have motivated the search for 
novel molecules for the synthesis of gold na-
noparticles. 
Levofloxacin (LvN) which is chemically 
(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-me-
thylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-
de]-1,4-benzoxazine-6-carboxylic acid, is a 
broad spectrum fluoroquinolone antibiotic 
active against both Gram positive and Gram 
negative bacteria functioning by inhibiting 
the type II topoisomerase enzymes namely 
DNA gyrase and topoisomerase IV (Drlica 
and Zhao, 1997). It is recommended as a 
first-line treatment option by ‘Infectious 
Disease Society of America’ for catheter as-
sociated urinary tract infections in adults and 
in prosthetic joint infection in combination 
with rifampicin (Hooton et al., 2010; Osmon 
et al., 2013). 
Bromelain (BRN) is a proteolytic en-
zyme derived from the plant Ananas como-
sus belonging to family Bromeliaceae 
(Taussig and Batkin, 1988). It has shown an-
algesic, anti-inflammatory, anti-arthritis, an-
titumuor, anthelminthic, antimicrobial and 
several other pharmacological activities 
(Leipner et al, 2001; Beez et al, 2007; Ro-
wan et al., 1990; Praveen et al., 2014). It was 
found to be less toxic having mutagenic po-
tential (Castell et al., 1997; Chobotova et al., 
2010). Hence, the present study was aimed 
to develop bromelain capped gold nanoparti-
cles as the effective drug delivery carrier of 
the antibiotic levofloxacin and to evaluate 
the antibacterial potential of its bioconjugat-
ed form as compared to pure LvN alone. 
 
MATERIALS AND METHODS 
Chemicals and reagents 
All the chemicals and solvents used in 
the present investigation were of analytical 
grade. Levofloxacin was procured from Yar-
row Chem Products, Mumbai (India) and 
bromelain from Merck Chemicals Darm-
stadt, Germany. 
 
Synthesis of gold nanoparticles 
Gold nanoparticles (Au-NPs) were syn-
thesized by in vitro method. The 3 μl of 
1.0 mM H[AuCl4] prepared in 50 mM phos-
phate buffer was taken in 3 mL of freshly 
prepared bromelain (0.33 mg/mL) and incu-
bated at the temperature of 40 °C for 48 h in 
an incubator. The reaction mixture without 
bromelain was used as a control. To ensure 
the formation of nanoparticles, the samples 
were removed from the reaction mixture at 
regular intervals and analyzed by UV-visible 
spectroscopy. On completion of the reaction, 
Au-NPs were collected by centrifugation at 
30000 g for 30 min, washed twice with Mil-
liQ water and the excess bromelain was re-
moved by treating with 50 % ethanol (v/v) 
(Khan et al., 2015a). 
 
Bioconjugation of gold nanoparticles to 
levofloxacin 
Synthesized Au-NPs were bioconjugated 
to LvN by using 1-ethyl-3-(3-dimethyl-
amino-propyl)-carbodiimide (EDC) as the 
activator (Timkovich, 1977). The 5 mM 
EDC was added to the 5 ml reaction mixture 
containing 250 µg of LvN, 250 µg of Au-
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NPs and 50 mM MES/HEPES buffer 
(HiMedia laboratories, India) in aliquots 
within 3 h at 30 °C for the coupling process. 
The bioconjugates so formed were separated 
from unconjugated Au-NPs by passing the 
reaction mixture through Biogel P-30 gel fil-
tration column pre-equilibrated with 20 mM 
HEPES buffer (pH 6.0) containing 150 mM 
sodium chloride. The fractions were scanned 
between 200-900 nm and subsequently 
pooled. The pooled samples were then dia-
lyzed against distilled water and used for fur-
ther characterization (Khan et al., 2015b). 
The samples were removed at regular inter-
vals and analyzed in UV-visible spectrosco-
py (Shimadzu dual-beam spectrophotometer, 
model UV-1601 PC, Japan) at a resolution of 
1 nm to confirm the formation of ‘BRN 
capped Au-NPs’ and ‘levofloxacin conjugat-
ed with BRN capped Au-NPs’(Au-BRN-
LvN-NPs). 
 
Characterization of synthesized gold nano-
particles and bioconjugated gold nanoparti-
cles 
Measurement of mean particle size and zeta 
potential of ‘BRN capped Au-NPs’ and Au-
BRN-LvN-NPs 
The samples of ‘BRN capped Au-NPs’ 
and Au-BRN-LvN-NPs were sonicated sepa-
rately for 1 min and then, taken in a 
DTS0112-low volume disposable sizing cu-
vette of 1.5 mL for the measurement of mean 
particle size with a dynamic light scattering 
(DLS) particle size analyzer (Zetasizer 
Nano-ZS, model ZEN3600, Malvern Instru-
ment Ltd, Malvern, UK) (Akhtar et al., 
2014). Zeta potential values were also as-
sessed to check the stability of the gold na-
noparticles with a Malvern Zetasizer 
Nanosystem (Worcestershire, UK). 
Transmission electron microscopy of ‘BRN 
capped Au-NPs’ and Au-BRN-LvN-NPs 
Transmission electron microscopy 
(TEM) was analyzed by drop drying the so-
lution of biosynthesized ‘BRN capped Au-
NPs’ and Au-BRN-LvN-NPs on carbon 
coated TEM copper grids followed by meas-
urements on TEM (FEI Company, Tecnaiä 
G2 Spirit BioTWIN) at an accelerating volt-
age of 80 kV. 
Fourier transform infrared spectroscopy of 
‘BRN capped Au-NPs’ and Au-BRN-LvN-
NPs 
The Fourier transform infrared (FTIR) 
spectra of ‘BRN capped Au-NPs’ and Au-
BRN-LvN-NPs were recorded using Perkin-
Elmer Spectrum Two FT-IR (Perkin Elmer 
Inc., Tres Cantos, Madrid) equipped with a 
Universal attenuated total reflectance sam-
pling device and scanned at room tempera-
ture in transmission mode over the wave 
number range of 4000-650 cm-1 at a resolu-
tion of 4 cm-1. 
Drug loading efficiency of levofloxacin 
Drug loading efficiency of LvN was cal-
culated using UV-visible spectroscopy at the 
wavelength of 307 nm/526 nm where the 
standard curve of the pure drug LvN was es-
tablished and the amount of unbound LvN 
was calculated from it. The actual amount of 
bioconjugated LvN was calculated by sub-
tracting unbound LvN from the total amount 
of LvN added. The amount of bioconjugated 
LvN was calculated using the equation [ % 
bioconjugation = (amount of drug conjugat-
ed / total drug added) × 100]. 
 
Evaluation of antibacterial efficacy of bio-
conjugated levofloxacin, Au-BRN-LvN-NPs 
over pure levofloxacin alone 
The antibacterial efficacy of bioconju-
gated LvN (Au-BRN-LvN-NPs) was deter-
mined by evaluating the minimum inhibitory 
concentration (MIC) of Au-BRN-LvN-NPs 
and pure LvN against Gram positive bacteria 
Staphylococcus aureus (NCIM No. 2079) 
and Gram negative bacteria Eschereschia 
coli (NCIM No. 2065) (Amsterdam, 1996). 
The bacterial strains in mid logarithmic 
phase were harvested by centrifugation, 
washed with 10 mM sodium phosphate buff-
er (PB) of pH 7.4, and diluted to 2×105 col-
ony forming units per ml (CFU/mL) in PB 
containing 0.03 % Luria-Bertani (LB) broth. 
Au-BRN-LvN-NPs were serially diluted in 
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50 µL of LB medium in 96-well microtitre 
plates so as to achieve the desired concentra-
tions with bacterial inoculums (5×104 
CFU/well) and were incubated at 37 °C 
overnight. The MIC was taken as the lowest 
Au-BRN-LvN-NPs concentration at which 
growth was inhibited (Khan et al., 2008). For 
agar plate count method (Stenger et al., 
1998), 25 µL aliquot of bacteria (1×105 
CFU/mL) was incubated with 25 µL of sam-
ples at 37 °C for 2 h (Hamamoto et al., 
2002). The mixtures were 10-fold serially di-
luted in PB, plated on LB agar and then in-
cubated overnight at 37 °C. Bacterial colo-
nies were enumerated following the day. Af-
ter the determination of the MIC from the 
microtitre plate wells with no visible growth, 
the samples were removed for serial subcul-
tivation (2 µL) into microtitre plates contain-
ing 100 µL of broth/well and further incu-
bated for 24 h in order to determine the bac-
tericidal activity measurement (MBC), the 
lowest concentration at which there is no vis-
ible bacterial growth indicating 99.5 % kill-
ing of the original inoculums. The absorb-
ance of each well was measured at a wave-
length of 620 nm by microtitre plate reader 
(Bio-Rad laboratories Inc., India) and com-
pared with a control. Autoclaved water and 
‘BRN capped Au-NPs’ were used as a nega-
tive control for each experiment. The proce-
dure was repeated for the pure levofloxacin 
alone too. 
 
RESULTS 
Bioconjugation of gold nanoparticles to 
levofloxacin and drug loading efficiency of 
levofloxacin 
The plasmon band was observed for the 
wine red colloidal gold nanoparticles at 
522 nm in the UV-visible spectrum. The col-
loidal solution containing ‘BRN capped Au-
NPs’ had shown very intense and character-
istic pink red color. Two peaks were ob-
served in Au-BRN-LvN-NPs spectrum one 
at 307 nm and other one at 526 nm during ul-
traviolet (UV) spectroscopy (Figure 2). The 
drug loading efficiency of LvN was found to 
be 84.8 ± 2.41 %. 
 
Measurement of mean particle size and zeta 
potential of ‘BRN capped Au-NPs’ and Au-
BRN-LvN-NPs 
The diameter of Au-BRN-LvN-NPs was 
found to be 58.65 ± 2 nm while that of its 
unconjugated form ‘BRN capped Au-NPs’ 
as 38.11 ± 2 nm (Figure 3). The zeta poten-
tial of Au-BRN-LvN-NPs was found to be  
-9.01 mV and that of its unconjugated form 
‘BRN capped Au-NPs’ -13.8 mV (Figure 4). 
 
 
 
Figure 2: UV-visible absorption spectra of BRN capped gold nanoparticles conjugated with levofloxa-
cin (Au-BRN-LvN-NPs) 
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Figure 3: Dynamic light scattering (DLS) analysis of [A] BRN capped gold nanoparticles (BRN capped 
Au-NPs), and [B] BRN capped gold nanoparticles conjugated with levofloxacin (Au-BRN-LvN-NPs) 
 
Figure 4: Zetasizer analysis of [A] BRN capped gold nanoparticles conjugated with levoflox-
acin (Au-BRN-LvN-NPs), and [B] BRN capped gold nanoparticles (BRN capped Au-NPs). 
 
Transmission electron microscopy of ‘BRN 
capped Au-NPs’ and Au-BRN-LvN-NPs 
Surface morphological study of ‘BRN 
capped Au-NPs’ and Au-BRN-LvN-NPs 
showed the formation of spherical particles 
with the particle size of 11.4 nm of ‘BRN 
capped Au-NPs’. The particle size of Au-
BRN-LvN-NPs was found to be ~13.2 nm 
and it retained the spherical shape (Figure 5). 
 
Fourier transform infrared spectroscopy of 
‘BRN capped Au-NPs’ and Au-BRN-LvN-
NPs 
FTIR spectrum of ‘BRN capped Au-NPs’ 
is shown in Figure 6(A) which has showed 
the characteristic C–N stretch vibration fre-
quencies of monoalkyl guanidinium assigned 
to the observed IR bands at 1641, 1425-1256 
and 1100 cm-1. The band at 1760-1670 cm-1 
(s) showed the presence of C = O groups 
(amides at ~1640cm-1). FTIR spectrum of 
Au-BRN-LvN-NPs is shown in Figure 6(B) 
which has shown the presence of peak at 
1634.24 cm-1 due to the presence of C = O 
(str) of the amide I linkage and the presence 
of peak at 3338cm-1 due OH stretching vi-
brations. 
 
Evaluation of antibacterial efficacy of bio-
conjugated levofloxacin over free levoflox-
acin 
Percent inhibition of the bacteria was in-
creasing with increasing doses of the pure 
levofloxacin and Au-BRN-LvN-NPs. The 
MICs of Au-BRN-LvN-NPs against S. aure-
us (NCIM No. 2079) and E. coli (NCIM No. 
2065) were found to be 0.128 µg/ml and 
1.10 µg/ml respectively, whereas MICs of 
the pure levofloxacin against S. aureus and 
E. coli were found to be 0.547 µg/ml and 
1.96 µg/ml respectively (Figure 7). 
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Figure 5: Transmission electron microscopic (TEM) images of [A] BRN capped gold nanoparticles 
(BRN capped Au-NPs), and [B] BRN capped gold nanoparticles conjugated with levofloxacin (Au-
BRN-LvN-NPs) 
 
 
Figure 6: Fourier transform infrared (FTIR) spectra of [A] Pure levofloxacin, and [B] BRN capped gold 
nanoparticles conjugated with levofloxacin (Au-BRN-LvN-NPs) 
 
 
Figure 7: Plot of percent inhibition of bacterial strains versus different concentrations of [A] pure 
levofloxacin, and [B] BRN capped gold nanoparticles conjugated with levofloxacin (Au-BRN-LvN-NPs) 
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DISCUSSION 
The plasmon band was observed for the 
wine red colloidal Au-NPs at 522 nm in the 
UV-visible spectrum which is characteristic 
of Au-NPs (Liao et al., 2006). The colloidal 
solution containing ‘BRN capped Au-NPs’ 
had shown very intense and characteristic 
pink red color confirming the formation of 
Au-NPs. However, two peaks were observed 
during UV-Visible spectral analysis of Au-
BRN-LvN-NPs one at 307 nm due to aro-
matic acid transitions of LvN and other one 
at 526 nm due to red shift. This red shift in 
the plasmon band suggests different dielec-
tric environment which confers conjugation 
of LvN with ‘BRN capped Au-NPs’. The 
amount of bioconjugated LvN (Au-BRN-
LvN-NPs) was found to be 84.8 ± 2.41 % in-
dicating that the LvN was efficiently loaded 
on synthesized BRN capped Au-NPs by us-
ing EDC as the activator. 
DLS provides hydrodynamic diameter 
which includes inorganic core and the thin 
electric dipole layer of the solvent that ad-
heres to the surface of the nanoparticles 
(Akhtar et al., 2014). The diameter of Au-
BRN-LvN-NPs was found to be 58.65 ± 2 
nm while that of its unconjugated form 
‘BRN capped Au-NPs’ 38.11 ± 2 nm prov-
ing that bioconjugation of LvN has taken 
place to form Au-BRN-LvN-NPs. Zeta po-
tential gives an indication of the stability of a 
colloidal system against agglomeration. The 
zeta potential of Au-BRN-LvN-NPs was 
found to be -9.01 mV which is well in range 
to prevent agglomeration as compared to its 
unconjugated form ‘BRN capped Au-NPs’ 
which was found to be -13.8 mV supporting 
the absence of nanoparticle aggregation after 
conjugation. This change in zeta potential 
may be ascribed to the decrease in number of 
carboxylic groups which are involved in con-
jugation of LvN. 
During surface morphological study by 
TEM, the particle size of Au-BRN-LvN-NPs 
was found to be ~13.2 nm while that of 
‘BRN capped Au-NPs’ as 11.4 nm. It is in 
coherence with the DLS and further corrobo-
rates bionconjugation of LvN with ‘BRN 
capped Au-NPs’ and supports the absence of 
aggregation of nanoparticles after bioconju-
gation. 
From the results of the study, it was 
found that the percent inhibition of the bacte-
ria S. aureus and E. coli were increasing with 
increasing doses of pure levofloxacin and 
Au-BRN-LvN-NPs suggesting their antibac-
terial activity against S. aureus and E. coli in 
dose dependent manner. The functionalized 
nanoparticles showed superior antibacterial 
activity compared to pure LvN at the similar 
concentration. From the results of the study, 
it is also clear that there was reduction in the 
IC50 values from 0.547 µg/ml and 1.96 µg/ml 
of pure LvN to 0.128 µg/ml and 1.10 µg/ml 
of Au-BRN-LvN-NPs against S. aureus and 
E. coli respectively which may be attributed 
to disruptions in the cell wall and membrane 
structures of bacteria by it leading to loss of 
cellular integrity and finally cell death. The 
IC50 value for Au-BRN-LvN-NPs was less 
against S. aureus as compared to that of E. 
coli suggesting that Au-BRN-LvN-NPs are 
more effective against S. aureus bacterium. 
On the other hand, Au-BRN-LvN-NPs are 
also able to generate reactive oxygen species 
which may play a synergistic role in killing 
bacteria (Nadeau et al., 2008). The probable 
reasons for superior antibacterial activity of 
Au-BRN-LvN-NPs may be its superior sta-
bility and transport of a huge number of LvN 
molecules into a highly localized area at the 
site of particle-bacterium contact (Burygin et 
al., 2009). 
 
CONCLUSION 
The results suggest that bromelain 
capped gold nanoparticles can be used as ef-
fective carriers for levofloxacin molecules. 
The bioconjugated bromelain capped gold 
nanoparticles exhibited superior antibacterial 
activity against both Gram negative and 
Gram positive bacteria compared to pure 
levofloxacin which may be due to its superi-
or stability and transport of a huge number of 
LvN molecules into a highly localized area at 
the site of particle-bacterium contact. 
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